Notice Pursuant to the National Cooperative Research and Production Act of 1993-SAE Consortium Ltd., 62867-62868 [07-5554]
Download as PDF
Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on July 13, 2007 (72 FR 38618).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5562 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to The National
Cooperative Research and Production
Act of 1993—Petroleum Environmental
Research Forum Project No. 2004–06
Notice is hereby given that, on March
15, 2007, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Petroleum
Environmental Research Forum
(‘‘PERF’’) Project No. 2004–06 has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
(1) the identities of the parties to the
venture and (2) the nature and
objectives of the venture. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the identities of the parties to the
venture are: BP Products North America
Inc., Naperville, IL; Citgo Petroleum
Corporation, Lemont, IL; ConocoPhillips
Company, bartlesville, OK; Marathon
Petroleum Company LLC, Findlay, OH;
YPF S.A., Mendoza, ARGENTINA; and
Total France, Paris, FRANCE. The
general area of PERF Project 2004–06’s
planned activity is to reduce desalter
environmental impacts.
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5567 Filed 11–06–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
pwalker on PROD1PC71 with NOTICES
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Portland Cement
Association
Notice is hereby given that, on
September 6, 2007, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
VerDate Aug<31>2005
19:26 Nov 06, 2007
Jkt 214001
15 U.S.C. 4301, et seq. (‘‘the Act’’),
Portland Cement Association (‘‘PCA’’)
has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Praxair, Inc., Danbury, CT,
has become an Associate Member.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and PCA intends
to file additional written notifications
disclosing all changes in membership.
On January 7, 1985, PCA filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on February 5, 1985 (50 FR 5015).
The last notification was filed with
the Department on May 14, 2007. A
notice as published in the Federal
Register pursuant to Section 6(b) of the
Act on July 13, 2007 (72 FR 38619).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5563 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—PXI Systems Alliance,
Inc.
Notice is hereby given that, on August
7, 2007, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301,
et seq. (‘‘the Act’’), PXI Systems
Alliance, Inc. has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Invisar, Inc., Chapel Hill,
NC; and Triple E Corporation, Lowell,
MA have withdrawn as parties to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
62867
project remains open, and PXI Systems
Alliance, Inc. intends to file additional
written notifications disclosing all
changes in membership.
On November 22, 2000, PXI Systems
Alliance, Inc. filed its original
notification pursuant to Section 6(a) of
the Act. The Department of Justice
published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on March 8, 2001 (66 FR 13971).
The last notification was filed with
the Department on May 30, 2007. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on July 13, 2007 (72 FR 38619).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5560 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—SAE Consortium Ltd.
Notice is hereby given that, on
September 27, 2007, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), SAE
Consortium Ltd. (‘‘SAEC’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
(1) the identities of the parties to the
venture and (2) the nature and
objectives of the venture. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the identities of the parties to the
venture are: Abbott Laboratories, Abbott
Park, IL; F. Hoffmann-La Roche, Inc.,
Basel, SWITZERLAND; Johnson &
Johnson Pharmaceutical Research &
Development, LLC, Raritan, NJ; Pfizer,
Inc., New York, NY; Sanofi-Aventis,
Bridgewater, NJ; SmithKline Beecham
Corporation d/b/a GlaxoSmithKline,
Research Triangle Park, NC; and Wyeth
Pharmaceuticals Inc., Collegeville, PA.
The SAEC’s general area of planned
activities is to carry out scientific
research in the public interest,
including research directed toward the
discovery of DNA-variants that are
clinically useful in understanding and
predicting the risk of drug induced
serious adverse events and similar
scientific research, the results of which
E:\FR\FM\07NON1.SGM
07NON1
62868
Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices
will then be made freely available to the
public on a nondiscriminatory basis.
The venture will enable SAEC to
identify DNA-variants useful in
understanding and predicting the risk of
drug induced serious adverse events
with shared financial risk and without
the duplication of effort that would
result from the work of individual
members. As the research results are
gathered, they will be placed in the
public domain for use by the worldwide
medical research community in
identifying specific genes involved in
causing serious adverse events, thereby
facilitating downstream research and
development of therapeutic diagnostic
and pharmaceutical products.
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5554 Filed 11–06–07; 8:45 am]
intends to file additional written
notifications disclosing all changes in
membership.
On May 27, 2003, Semiconductor Test
Consortium, Inc. filed its original
notification pursuant to Section 6(a) of
the Act. The Department of Justice
published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on June 17, 2003 (68 FR 35913).
The last notification was filed with
the Department on June 7, 2007. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on July 13, 2007 (72 FR 38619).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5552 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
BILLING CODE 4410–11–M
Antitrust Division
DEPARTMENT OF JUSTICE
Antitrust Division
pwalker on PROD1PC71 with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Semiconductor Test
Consortium, Inc.
Notice is hereby given that, on August
22, 2007, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301,
et seq. (‘‘the Act’’), Semiconductor Test
Consortium, Inc. has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Tom Jackson (individual
member), Merrimack, NH; Wavecrest
Corporation, Eden Prairie, MN; Keven
Fetterly (individual member),
Rollingbay, WA; and Mark Roos
(individual member), Santa Clara, CA
have been added as parties to this
venture. Also, NXP Semiconductors,
Inc., San Jose, CA; John Rowe
(individual member), Boston, MA;
Christopher Alderson (individual
member), Yokohama, JAPAN; Apria
Technology, Rollingbay, WA; and Roos
Instruments, Santa Clara, CA have
withdrawn as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and
Semiconductor Test Consortium, Inc.
VerDate Aug<31>2005
16:14 Nov 06, 2007
Jkt 214001
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on High Efficiency Dilute
Gasoline Engine (HEDGE)
Notice is hereby given that, on June 1,
2007, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Southwest Research
Institute (‘‘SwRI’’): Cooperative
Research Group on High Efficiency
Dilute Gasoline Engine (‘‘HEDGE’’) has
filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Honda R&D Co., Ltd,
Tochigi Prefecture, JAPAN has been
added as a party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and HEDGE
intends to file additional written
notifications disclosing all changes in
membership.
On June 10, 2005, HEDGE filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on July 7, 2005 (70 FR 39339–
39340).
The last notification was filed with
the Department on April 5, 2007. A
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on May 7, 2007 (72 FR 25782).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5559 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on Common Rail Fuel Systems
Notice is hereby given that, on August
15, 2007, pursuant to Section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Southwest Research
Institute (‘‘SwRI’’): Cooperative
Research Group on Common Rail Fuel
Systems filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing (1) the identities
of the participants in the cooperative
research project and (2) the nature and
objectives of the venture. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the identities of the current participants
in the Cooperative Research Group on
Common Rail Fuel Systems are:
Baldwin Filters, Kearney, NE;
Caterpillar, Inc., Mossville, IL;
Champion Laboratories, Inc., Albion, IL;
Donaldson, Minneapolis, MN; Komatsu,
Oyamo-shi, Japan; Racor, Modesto, Ca.
The purpose and nature of the
Cooperative Research Group on
Common Rail Fuel Systems is to
determine the filtration requirements
needed to control significant abrasive
wear, and to determine the most
sensitive areas in the fuel injection
system to identify critical components.
To attain such, a filtration assessment
system and test protocol for testing
future systems will be developed. The
test protocol will include conditions,
such as vibration, to determine
environmental factors that may affect
the protocol and the protocol will be
verified by different degrees of filtration
using various common rail systems. A
standardized filter test method to meet
industry standards will also be
recommended.
Membership in this research group
remains open, and the participants
E:\FR\FM\07NON1.SGM
07NON1
Agencies
[Federal Register Volume 72, Number 215 (Wednesday, November 7, 2007)]
[Notices]
[Pages 62867-62868]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-5554]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--SAE Consortium Ltd.
Notice is hereby given that, on September 27, 2007, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), SAE Consortium Ltd.
(``SAEC'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing (1) the
identities of the parties to the venture and (2) the nature and
objectives of the venture. The notifications were filed for the purpose
of invoking the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Pursuant to Section 6(b) of the Act, the identities of the parties
to the venture are: Abbott Laboratories, Abbott Park, IL; F. Hoffmann-
La Roche, Inc., Basel, SWITZERLAND; Johnson & Johnson Pharmaceutical
Research & Development, LLC, Raritan, NJ; Pfizer, Inc., New York, NY;
Sanofi-Aventis, Bridgewater, NJ; SmithKline Beecham Corporation d/b/a
GlaxoSmithKline, Research Triangle Park, NC; and Wyeth Pharmaceuticals
Inc., Collegeville, PA. The SAEC's general area of planned activities
is to carry out scientific research in the public interest, including
research directed toward the discovery of DNA-variants that are
clinically useful in understanding and predicting the risk of drug
induced serious adverse events and similar scientific research, the
results of which
[[Page 62868]]
will then be made freely available to the public on a nondiscriminatory
basis. The venture will enable SAEC to identify DNA-variants useful in
understanding and predicting the risk of drug induced serious adverse
events with shared financial risk and without the duplication of effort
that would result from the work of individual members. As the research
results are gathered, they will be placed in the public domain for use
by the worldwide medical research community in identifying specific
genes involved in causing serious adverse events, thereby facilitating
downstream research and development of therapeutic diagnostic and
pharmaceutical products.
Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. 07-5554 Filed 11-06-07; 8:45 am]
BILLING CODE 4410-11-M